# FDA Inspection 1259886 - Suzhou Lixin Pharmaceutical Co. Ltd. - August 30, 2023

Source: https://www.keypedia.com/records/fda_inspections/suzhou-lixin-pharmaceutical-co-ltd/774fa5a0-216c-4fc9-9bf3-04eb43b7a985
Source feed: FDA_Inspections

> FDA Inspection 1259886 for Suzhou Lixin Pharmaceutical Co. Ltd. on August 30, 2023. Classification: Voluntary Action Indicated (VAI).

---

## Details

- Record Type: FDA Inspection
- Inspection ID: 1259886
- Company Name: Suzhou Lixin Pharmaceutical Co. Ltd.
- Inspection Date: 2023-08-30
- Classification: Voluntary Action Indicated (VAI)
- Project Area: Drug Quality Assurance
- Product Type: Drugs
- Office Name: Center for Drug Evaluation and Research

## Related Documents

- [FDA Inspection 918374 - 2015-03-13](https://www.keypedia.com/records/fda_inspections/suzhou-lixin-pharmaceutical-co-ltd/a81073ff-6e55-4d96-b8a2-e60f24bc98fb)

Company: https://www.keypedia.com/companies/suzhou-lixin-pharmaceutical-co-ltd/2ad0b1cc-f2ce-4670-9844-bde1417dd946

Office: https://www.keypedia.com/offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c